Biodistribution study of lutetium hydroxyapatite (177Lu-HA) for liver cancer therapy

This study aimed to determine the organ at risk (OAR) of 177Lu-HA in liver cancer therapy using the biodistribution study and model selections method. Administration of 177Lu-HA was carried out directly on the intra-artery of Wistar rat liver by surgery. Pharmacokinetics data of 177Lu-HA in Wistar rats from different organs, such as liver, kidneys, and spleen, were obtained from the literature. Thirteen sums of exponentials (SOE) functions and one logistic function were used and fitted to the pharmacokinetics data in different organs. The goodness of fit was tested based on the visualization of the fitted graphs, coefficient of variations of the fitted parameters (CV